Amgen TAPs second ImmunoGen licence
This article was originally published in Scrip
Executive Summary
Amgen has exclusively licensed ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second such licence to be taken by Amgen – it obtained the exclusive right to use ImmunoGen’s TAP technology for another undisclosed cancer target earlier this year (scripnews.com, September 22nd, 2009).